About Us

FSD Pharma, Inc. is a publicly traded holding company, since May 2018. It trades on NASDAQ as well as on the CSE, under the symbol HUGE

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its exclusive compounds and NCEs (New Chemical Entities)

The first exclusive rights that FSD acquired was for FSD201 which is ultra-micronized palmitoylethanolamide (PEA). Ultra-Micro PEA stabilizes mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of the endocannabinoid system of the human body. FSD Pharma has successfully completed the Phase 1 trial for this compound with topline results, and is now contemplating the most viable condition medical condition to go for, the phase 2 trials, to prove the efficacy of this compound

In August 2021, FSD Pharma entered into a definitive agreement to acquire 100% shares of Lucid Psycheceuticals. The closing of this transaction is expected in the last week of September provided that the terms of the definitive agreement are met. Lucid Psycheceuticals Inc., a psychedelic pharmaceutical company with exclusive worldwide licensing rights, from the University Health Network (UHN) North America’s largest health research organization, to a family of new chemical entities that offer the ability to prevent, and reverse Neurodegenerative orders of the brain. The company plans to apply these patented molecules in conjunction with psychedelic-inspired compounds through a unique novel approach called “Total Brain Health”. Together, these unique therapies have the potential to enhance the brain’s ability to absorb, repair and protect itself, and are being developed with the ultimate aim to help treat serious neurodegenerative diseases such as Progressive Multiple Sclerosis.

Through the acquisition of Lucid Psycheceuticals, FSD Pharma will not only be able to expand and add to it’s family of proprietary molecules with exclusive worldwide rights, but will also be entering the field of medical psychedelics, and will be applying a unique approach called “Total Brain Health” to treat Neurodegenerative disorders.

The Company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently being dispensed in Italy and Spain as a prescription based medical food supplement since 2004.